Bezisterim Phase 2 results highlight potential new treatment approach for Parkinson’s disease symptoms
BioVie's bezisterim shows promising Phase 2 Parkinson's results in patients with elevated inflammation. Explore the findings and Phase 3 outlook.
Pharma & Biotech